Key regions: Germany, United States, India, Japan, United Kingdom
Anti-Rheumatic Drugs are used to treat rheumatoid arthritis, a chronic autoimmune disease that affects the joints. In Norway, the market for Anti-Rheumatic Drugs has been showing some interesting developments.
Customer preferences: Norwegian customers prefer Anti-Rheumatic Drugs that are effective in reducing inflammation and pain, while also having minimal side effects. They also value drugs that are easy to administer and have a low cost.
Trends in the market: One trend in the Norwegian Anti-Rheumatic Drugs market is the increasing use of biologic drugs. These drugs are made from living organisms and are designed to target specific parts of the immune system that are involved in causing inflammation. Biologic drugs have been shown to be very effective in treating rheumatoid arthritis, but they are also more expensive than traditional drugs. Despite the higher cost, many Norwegian patients are willing to pay for the improved efficacy and lower side effects of biologic drugs.Another trend in the Norwegian market is the growing use of biosimilars. Biosimilars are drugs that are similar to biologic drugs, but are not identical. They are designed to have similar efficacy and safety profiles as the original biologic drugs, but at a lower cost. The use of biosimilars has been increasing in Norway due to government policies that encourage the use of lower-cost drugs.
Local special circumstances: Norway has a relatively small population, which means that the market for Anti-Rheumatic Drugs is also relatively small. This can make it challenging for pharmaceutical companies to justify investing in research and development for new drugs. However, the Norwegian government has implemented policies to encourage the use of innovative drugs, which has helped to stimulate the market.
Underlying macroeconomic factors: The Norwegian economy has been relatively stable in recent years, with low unemployment and steady economic growth. This has helped to support the market for Anti-Rheumatic Drugs, as patients are able to afford the high cost of biologic drugs. Additionally, the Norwegian healthcare system provides universal coverage for all citizens, which means that patients have access to the drugs they need regardless of their ability to pay.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
